Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH - Get Free Report) CMO Randall Kaye sold 16,667 shares of the stock in a transaction dated Tuesday, October 15th. The stock was sold at an average price of $59.03, for a total value of $983,853.01. Following the sale, the chief marketing officer now owns 17,920 shares of the company's stock, valued at approximately $1,057,817.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Randall Kaye also recently made the following trade(s):
- On Monday, September 16th, Randall Kaye sold 16,666 shares of Longboard Pharmaceuticals stock. The stock was sold at an average price of $31.64, for a total value of $527,312.24.
- On Monday, August 12th, Randall Kaye sold 16,667 shares of Longboard Pharmaceuticals stock. The stock was sold at an average price of $34.73, for a total transaction of $578,844.91.
Longboard Pharmaceuticals Stock Up 0.5 %
Shares of Longboard Pharmaceuticals stock opened at $59.40 on Thursday. The company has a market cap of $2.31 billion, a PE ratio of -26.52 and a beta of 1.22. Longboard Pharmaceuticals, Inc. has a 52 week low of $3.60 and a 52 week high of $59.47. The business has a 50 day moving average price of $35.87 and a 200-day moving average price of $28.31.
$20 = Ounce of Gold?
From Monument Traders Alliance | Ad
I've discovered a way to get exposure to MORE than an ounce of gold... for under $20.
It's not bullion. It's not ETFs. And it's certainly not crypto.
Click here to find out why this is my favorite gold stock.
Longboard Pharmaceuticals (NASDAQ:LBPH - Get Free Report) last released its quarterly earnings results on Thursday, August 1st. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.10). During the same quarter last year, the firm earned ($0.65) earnings per share. As a group, research analysts anticipate that Longboard Pharmaceuticals, Inc. will post -2.19 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently made changes to their positions in the company. Ameritas Investment Partners Inc. increased its stake in Longboard Pharmaceuticals by 93.3% in the 1st quarter. Ameritas Investment Partners Inc. now owns 2,486 shares of the company's stock valued at $54,000 after buying an additional 1,200 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new position in shares of Longboard Pharmaceuticals in the second quarter valued at approximately $127,000. SG Americas Securities LLC purchased a new stake in shares of Longboard Pharmaceuticals during the first quarter valued at approximately $132,000. Denali Advisors LLC bought a new stake in Longboard Pharmaceuticals during the first quarter worth $201,000. Finally, Arizona State Retirement System purchased a new position in Longboard Pharmaceuticals in the second quarter worth $216,000. 63.28% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
Several research analysts recently issued reports on LBPH shares. Truist Financial reissued a "hold" rating and set a $60.00 target price on shares of Longboard Pharmaceuticals in a research note on Tuesday. B. Riley restated a "neutral" rating and issued a $60.00 target price (up from $45.00) on shares of Longboard Pharmaceuticals in a research note on Monday. Evercore ISI reaffirmed an "outperform" rating and set a $80.00 price target on shares of Longboard Pharmaceuticals in a research note on Monday, August 26th. HC Wainwright reissued a "neutral" rating and issued a $60.00 price objective (down previously from $80.00) on shares of Longboard Pharmaceuticals in a research note on Tuesday. Finally, Wedbush lowered Longboard Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Monday. Five analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, Longboard Pharmaceuticals has a consensus rating of "Hold" and a consensus target price of $59.56.
Read Our Latest Report on LBPH
Longboard Pharmaceuticals Company Profile
(
Get Free Report)
Longboard Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
